pf-05180999
Small moleculeexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2011 (NCT01429740)
Timeline
2010s
- Jan 1, 2011
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Phosphodiesterase 2AINHIBITOR
PDE2A inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cc1nc(-c2cnn(C)c2-c2ccc(C(F)(F)F)cn2)c2c(N3CCC3)ncnn12- Mol. weight
- 414.4 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3092562 ↗
Also known as
- pf-05180999
- pf-05180999
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01981486 | Phase 1 | Jun 1, 2014 | Pfizer |
| NCT01981499 | Phase 1 | Jan 1, 2014 | Pfizer |
| NCT01530529 | Phase 1 | Jan 1, 2012 | Pfizer |
| NCT01429740 | Phase 1 | Aug 1, 2011 | Pfizer |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 4 | 4 | 1 | 2011 |
1 organizations
Page 1 / 1